{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Empagliflozin&page=5",
    "query": {
      "intervention": "Empagliflozin",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 142,
    "total_pages": 15,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Empagliflozin&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Empagliflozin&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-17T02:40:44.704Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05220917",
      "title": "Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cardiovascular Events",
        "Type2 Diabetes",
        "Renal Disease"
      ],
      "interventions": [
        {
          "name": "SGLT2 inhibitor",
          "type": "DRUG"
        },
        {
          "name": "DPP-4 inhibitor",
          "type": "DRUG"
        },
        {
          "name": "GLP-1RA",
          "type": "DRUG"
        },
        {
          "name": "2nd generation SU",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 781430,
      "start_date": "2021-08-01",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-13",
      "last_synced_at": "2026-10-17T02:40:44.704Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05220917"
    },
    {
      "nct_id": "NCT05078879",
      "title": "Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Crohn's Disease",
        "Glycogen Metabolism",
        "Inflammatory Bowel Disease (IBD)"
      ],
      "interventions": [
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 4,
      "start_date": "2021-11-16",
      "completion_date": "2025-05-21",
      "has_results": false,
      "last_update_posted_date": "2025-06-26",
      "last_synced_at": "2026-10-17T02:40:44.704Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05078879"
    },
    {
      "nct_id": "NCT04509674",
      "title": "EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Myocardial Infarction"
      ],
      "interventions": [
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6522,
      "start_date": "2020-12-16",
      "completion_date": "2023-11-05",
      "has_results": true,
      "last_update_posted_date": "2025-01-07",
      "last_synced_at": "2026-10-17T02:40:44.704Z",
      "location_count": 85,
      "location_summary": "Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 75 more",
      "locations": [
        {
          "city": "Alexander City",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04509674"
    },
    {
      "nct_id": "NCT03429543",
      "title": "Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Insulin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Linagliptin",
          "type": "DRUG"
        },
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "10 Years to 17 Years"
      },
      "enrollment_count": 175,
      "start_date": "2018-03-20",
      "completion_date": "2023-05-31",
      "has_results": true,
      "last_update_posted_date": "2024-02-23",
      "last_synced_at": "2026-10-17T02:40:44.704Z",
      "location_count": 44,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Orange, California + 39 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03429543"
    },
    {
      "nct_id": "NCT03152552",
      "title": "A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus and Heart Failure"
      ],
      "interventions": [
        {
          "name": "LIK066",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 125,
      "start_date": "2017-07-25",
      "completion_date": "2018-06-06",
      "has_results": true,
      "last_update_posted_date": "2019-08-28",
      "last_synced_at": "2026-10-17T02:40:44.704Z",
      "location_count": 21,
      "location_summary": "Huntsville, Alabama • Carmichael, California • Concord, California + 18 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Carmichael",
          "state": "California"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03152552"
    },
    {
      "nct_id": "NCT06506422",
      "title": "Empagliflozin Reversal of Arterial StiffnEss in Aging",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Aging",
        "Arterial Stiffness"
      ],
      "interventions": [
        {
          "name": "Empagliflozin 10 MG",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Missouri-Columbia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "60 Years to 80 Years"
      },
      "enrollment_count": 80,
      "start_date": "2024-08-18",
      "completion_date": "2029-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-02-06",
      "last_synced_at": "2026-10-17T02:40:44.704Z",
      "location_count": 1,
      "location_summary": "Columbia, Missouri",
      "locations": [
        {
          "city": "Columbia",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06506422"
    },
    {
      "nct_id": "NCT05390892",
      "title": "PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type2Diabetes",
        "ASCVD"
      ],
      "interventions": [
        {
          "name": "SGLT2 inhibitor",
          "type": "DRUG"
        },
        {
          "name": "GLP-1 receptor agonist",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 6000,
      "start_date": "2022-09-26",
      "completion_date": "2029-03-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-10-17T02:40:44.704Z",
      "location_count": 36,
      "location_summary": "Huntsville, Alabama • Scottsdale, Arizona • Los Angeles, California + 31 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Pembroke Pines",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05390892"
    },
    {
      "nct_id": "NCT04917692",
      "title": "Empagliflozin in Adolescent Diabetes",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "type1diabetes"
      ],
      "interventions": [
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ohio State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "12 Years to 18 Years"
      },
      "enrollment_count": 0,
      "start_date": "2021-07",
      "completion_date": "2022-10",
      "has_results": false,
      "last_update_posted_date": "2023-03-23",
      "last_synced_at": "2026-10-17T02:40:44.704Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04917692"
    },
    {
      "nct_id": "NCT01370005",
      "title": "12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2",
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "BI 10773",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 825,
      "start_date": "2011-06",
      "completion_date": "2012-07",
      "has_results": true,
      "last_update_posted_date": "2016-02-22",
      "last_synced_at": "2026-10-17T02:40:44.704Z",
      "location_count": 35,
      "location_summary": "Huntsville, Alabama • Phoenix, Arizona • Lincoln, California + 29 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Lincoln",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01370005"
    },
    {
      "nct_id": "NCT07053293",
      "title": "SGLT2i, Hepatic Glucose Production, and SNS",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Empagliflozin 25 MG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "30 Years to 75 Years"
      },
      "enrollment_count": 22,
      "start_date": "2025-01-07",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-17",
      "last_synced_at": "2026-10-17T02:40:44.704Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07053293"
    }
  ]
}